Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 18: 330-334, 1972;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dalal, F. R.
Right arrow Articles by Winsten, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalal, F. R.
Right arrow Articles by Winsten, S.

Clinical Chemistry, Vol 18, 330-334, Copyright © 1972 by the American Association for Clinical Chemistry

A Study of the Problems of Inactivation of Creatine Kinase in Serum

Fram R. Dalal 1, Jonathan Cilley Jr. 1, and Seymour Winsten 1

1 Section of Chemistry, Division of Laboratories, Albert Einstein Medical Center, Philadelphia, Pa. 19141.

Addition of sulfhydryl groups to the reaction mixture, to stabilize serum creatine kinase (creatine phosphokinase, CPK), results in apparent increases in the activity of this enzyme in many sera. In addition, in sera from patients just after myocardial infarction, assays for sulfhydryl-activated CPK have a different clinical pattern than do those for CPK assayed without sulfhydryl activators: activities are greater and remain abnormally high longer in assays in which the enzyme is sulfhydryl activated. If the assay is done without sulfhydryl activators present, technical difficulties appear, because CPK in serum is rapidly inactivated at room temperature. CPK is apparently inactivated in at least two ways. One, which is irreversible, is inhibited by albumin; the other, which is reversible by sulfhydryl groups, seems to result from the presence of substances in the pooled serum used that are both protein bound and free.


Key Words: progressive muscular dystrophy • sulfhydryl groups as activators • Cleland’s reagent • inactivator in serum • myocardial infarction • AutoAnalyzer

Submitted on November 15, 1971
Accepted on December 28, 1971




The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Pathol.Home page
N Durany, J Carreras, M Valenti, J Camara, and J Carreras
Inactivation of phosphoglycerate mutase and creatine kinase isoenzymes in human serum
Mol. Pathol., August 1, 2002; 55(4): 242 - 249.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American Association for Clinical Chemistry.